Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?
E. Zamarron De Lucas (Madrid, Spain), D. Romero Ribate (Madrid, Spain), J. Fernández-Lahera Martínez (Madrid, Spain), C. Villasante Fernández-Montes (Madrid, Spain), S. Quirce Gancedo (Madrid, Spain), P. Barranco Sanz (Madrid, Spain), J. Domínguez Ortega (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain)
Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1038
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Zamarron De Lucas (Madrid, Spain), D. Romero Ribate (Madrid, Spain), J. Fernández-Lahera Martínez (Madrid, Spain), C. Villasante Fernández-Montes (Madrid, Spain), S. Quirce Gancedo (Madrid, Spain), P. Barranco Sanz (Madrid, Spain), J. Domínguez Ortega (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain). Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients?. 1038
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017
Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007
Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Asthma patients adjust their maintenance treatment late in response to worsening asthma symptoms Source: Eur Respir J 2005; 26: Suppl. 49, 7s Year: 2005
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Factors resulting in uncontrolled severe persistent asthma in children Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021
Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021
The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Effect of maintenance oral corticosteroids on risk factors for frequent exacerbations in a severe adult asthma population Source: Virtual Congress 2020 – Severe asthma phenotypes and outcomes Year: 2020
Factors associated with frequent exacerbations in patients with severe asthma Source: Eur Respir J 2001; 18: Suppl. 33, 369s Year: 2001